BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32253579)

  • 21. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma.
    Basile G; Rosiello G; Larcher A; Fallara G; Martini A; Re C; Cignoli D; Tian Z; Karakiewicz PI; Mottrie A; Bertini R; Necchi A; Raggi D; Salonia A; Briganti A; Montorsi F; Capitanio U
    Urol Oncol; 2022 Aug; 40(8):384.e15-384.e21. PubMed ID: 35662498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
    Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
    Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
    Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
    Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extent of lymph node dissection improves overall survival in pT3N0 non-metastatic renal cell carcinoma patients treated with radical nephrectomy: a propensity score-based analysis.
    Wei Y; Wang M; Jin Y; Zhou C; Lyu J
    World J Urol; 2020 Jun; 38(6):1579-1585. PubMed ID: 31065795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
    Zhao H; Leppert JT; Peehl DM
    PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor.
    Mai KT; Landry DC; Robertson SJ; Commons AS; Burns BF; Thijssen A; Collins J
    Pathol Res Pract; 2001; 197(10):671-5. PubMed ID: 11700888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.
    Gershman B; Thompson RH; Moreira DM; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
    J Urol; 2017 Mar; 197(3 Pt 1):574-579. PubMed ID: 27663461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
    J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
    Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
    BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
    Hanna N; Sun M; Meyer CP; Nguyen PL; Pal SK; Chang SL; de Velasco G; Trinh QD; Choueiri TK
    J Clin Oncol; 2016 Sep; 34(27):3267-75. PubMed ID: 27325852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery.
    Ledezma RA; Negron E; Paner GP; Rjepaj C; Lascano D; Haseebuddin M; Dangle P; Shalhav AL; Crist H; Raman JD; Joel DeCastro G; Harik L; Paroder M; Uzzo RG; Kutikov A; Eggener SE
    World J Urol; 2016 May; 34(5):687-93. PubMed ID: 26407582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Papillary type 2 versus clear cell renal cell carcinoma: Survival outcomes.
    Simone G; Tuderti G; Ferriero M; Papalia R; Misuraca L; Minisola F; Costantini M; Mastroianni R; Sentinelli S; Guaglianone S; Gallucci M
    Eur J Surg Oncol; 2016 Nov; 42(11):1744-1750. PubMed ID: 27593224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
    Pal SK; Nelson RA; Vogelzang N
    PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis.
    Yang C; Shuch B; Kluger H; Humphrey PA; Adeniran AJ
    Am J Surg Pathol; 2020 May; 44(5):582-593. PubMed ID: 32101890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
    Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
    PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.